Stockscreener 앱 받기
1.27
3.05%
-0.04
시간 외 거래:
1.34
0.07
+5.51%
전일 마감가:
$1.31
열려 있는:
$1.3
하루 거래량:
19,644
Relative Volume:
0.15
시가총액:
$3.89M
수익:
$129.20K
순이익/손실:
$-7.44M
주가수익비율:
-0.1135
EPS:
-11.19
순현금흐름:
$-8.62M
1주 성능:
-3.05%
1개월 성능:
-15.89%
6개월 성능:
-75.36%
1년 성능:
-91.89%
1일 변동 폭
$1.24
$1.305
1주일 범위
$1.22
$1.35
52주 변동 폭
$1.22
$16.80
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
명칭
Sonnet Biotherapeutics Holdings Inc
전화
609-375-2227
주소
100 OVERLOOK CENTER, PRINCETON, NJ
SONN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
1.27 | 3.89M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Sonnet Biotherapeutics Holdings Inc 주식(SONN)의 최신 뉴스
Sonnet Announces Release of Corporate Update Video - GlobeNewswire
Sonnet BioTherapeutics appoints interim CEO and new president By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics appoints interim CEO and new president - Investing.com
Pilot Killed In Franklin Twp Plane Crash Was CEO Of Cancer-Focused Biotech Company - dailyvoice.com
Sonnet BioTherapeutics appoints interim CEO after founder’s death - Investing.com
Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. - GlobeNewswire
Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan - MarketScreener
Leadership Change at Sonnet BioTherapeutics: Founder Passes, New Executive Team Steps In - Stock Titan
Chardan Capital Reaffirms Buy Rating for Sonnet BioTherapeutics (NASDAQ:SONN) - Defense World
Sonnet BioTherapeutics’ (SONN) Buy Rating Reaffirmed at Chardan Capital - The AM Reporter
SONN stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia
Sonnet BioTherapeutics Successfully Completes First Safety - GlobeNewswire
Sonnet BioTherapeutics Successfully Completes First Safety Review Of SON-1010 In Combination With Trabectedin In Certain Sarcomas - MarketScreener
Clinical Trial Success: New Cancer Drug Combo Shows 83% Disease Control in Sarcoma Patients - Stock Titan
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) Short Interest Up 16.4% in February - Defense World
Sonnet BioTherapeutics secures new IL-18 patent - Investing.com
Sonnet BioTherapeutics secures new IL-18 patent By Investing.com - Investing.com South Africa
Sonnet BioTherapeutics Secures Second Patent for IL-18 Variant - TipRanks
Sonnet BioTherapeutics Receives Notice of Allowance for - GlobeNewswire
Major Patent Win: Sonnet's Revolutionary IL-18 Cancer Treatment Shows Superior Binding Properties - StockTitan
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference - Nasdaq
Sonnet Bio CEO Unveils 5 Game-Changing Developments Coming in 2025 - StockTitan
XRP Plunges as Recession Panic and Crypto Summit Fallout Slam Investors - The Globe and Mail
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
SONN stock touches 52-week low at $1.33 amid market challenges - Investing.com UK
Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update - ACCESS Newswire
Sonnet BioTherapeutics Highlights Promising SON-1010 Data - TipRanks
Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors - The Manila Times
Sonnet BioTherapeutics Presents Innovative FHAB® Platform Data at 2025 AACR:IO Conference - Nasdaq
Sonnet BioTherapeutics Presents Compilation of Data - GlobeNewswire
Can This Immunotherapy Beat Solid Tumors? Sonnet's SON-1010 Shows 48% Clinical Benefit - StockTitan
Sonnet BioTherapeutics Announces Availability of Proprietary ADC Platform for Drug Discovery Partnerships - The AM Reporter
Sonnet BioTherapeutics advances novel ADC platform By Investing.com - Investing.com Australia
Sonnet BioTherapeutics advances novel ADC platform - Investing.com
SONN stock touches 52-week low at $1.38 amid market challenges - Investing.com India
Sonnet Biotherapeutics' Proprietary ADC Platform Available For Drug Discovery Partnerships - Marketscreener.com
Sonnet BioTherapeutics Announces That Its Proprietary - GlobeNewswire
Sonnet BioTherapeutics Advances Antibody Drug Conjugate Platform - TipRanks
2 Hot Growth Stocks Poised for Gains of Up to 370%, According to Wall Street - The Globe and Mail
Can This New ADC Platform Challenge Established Cancer Drugs? Preclinical Data Shows Promise - StockTitan
Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference - The Manila Times
Sonnet BioTherapeutics Announces Acceptance of Poster Presentation at 2025 AACR IO Conference - Nasdaq
Revolutionary Cancer Treatment Breakthrough: Sonnet's IL-12 Protein Research Heads to AACR 2025 - StockTitan
Sonnet BioTherapeutics appoints new chief business officer - MSN
Sonnet Biotherapeutics Holdings Inc (SONN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.23%
1.63%
자본화:
|
볼륨(24시간):